HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Comment by esviagraon Nov 06, 2014 2:52pm

173 Views

Post# 23103273

RE:Early Termination on Lease

I wish you are right, but the statement from newswire on Automodular result doesn't feel right

"In light of the closure of the Oakville operations and ongoing diversification efforts, the Board of Directors has elected not to declare a dividend in the fourth quarter of 2014. The Company will revisit its dividend policy in conjunction with its go forward plans in the first quarter of 2015 and will communicate with its stakeholders at that time."

Bullboard Posts

Gold opportunity in Australia’s Northern Territory shines bright